KOSDAQElectrical Equipment214680

Drtech

₩4,110▲ 5.12%2026-11-18 close
Market Cap
₩68.6B
Turnover
₩200M
Volume
50K
Shares out.
16.7M
PER
—
PBR
0.9×
EPS
-₩1,421
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales growth and quarterly profits; net losses remain the test

Drtech posted operating profits in the second and third quarters of 2026 as sales grew, but cumulative net losses attributable to controlling shareholders over the last four quarters of KRW 23.7 billion keep net profitability an open issue.

  1. 1

    Sales reached KRW 116.3 billion in 2025, up 19.2% from the prior year, and have risen for three consecutive years since 2023. The company said 2025 was the first year sales topped KRW 100 billion.

  2. 2

    The company recorded an operating loss for three consecutive years from 2023 to 2025, with a 2025 operating loss of KRW 13.9 billion.

  3. 3

    Third-quarter 2026 sales were KRW 34.5 billion, up 1.5% year on year, and operating profit was KRW 2.17 billion, up 29.8% year on year. Net loss attributable to controlling shareholders in the same quarter was KRW 8.34 billion.

  4. 4

    The debt-to-equity ratio stood at 163.0% at the end of 2025, and operating cash flow was KRW -20.1 billion, so the balance sheet remains an area for improvement.

  5. 5

    The business is heavily export-oriented. Exports reached KRW 95.4 billion in 2025, and cumulative sales passed KRW 100 billion within the first three quarters of 2026.

02

Business structure

Drtech makes detectors, the components that convert X-ray images into digital signals, and complete diagnostic imaging systems built around them, so it is a medical imaging company. Its sector classification is electrical equipment, but the underlying business is closer to medical devices.

By product, cumulative sales through the third quarter of 2026 were split 52% detectors, 20% X-ray systems, and 19% breast cancer diagnostic (mammography) systems.

The EXPEED dynamic detector series entered a market long dominated by companies in Japan, the United States and France, and volumes supplied to global corporate customers are rising; the company says related unit sales have roughly doubled each year.

On the complete-system side, the EXTRON C-arm and the AIDIA breast diagnostic system form the core. A supply agreement with a global healthcare company covers more than 600 C-arm units over five years.

In industrial testing, the company supplies bendable detectors for pipe weld inspection to A, a major North American non-destructive testing firm, and in November 2026 it received final-use approval from Saudi Aramco and ADNOC of the UAE.

On production, annual detector capacity rose from 10,752 units in 2023 to 13,536 units in 2025. Exports grew from KRW 74.3 billion in 2024 to KRW 95.4 billion in 2025, and the export share was 82% as of the third quarter of 2025.

Because sales are concentrated among a small number of global customers, the timing of large orders largely determines quarterly revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩34B₩1.7B4.9%
2025Q4₩23.3B-₩13B−55.5%
2026Q1₩31.8B-₩600M−1.9%
2026Q2₩37B₩1.9B5.0%
2026Q3₩34.5B₩2.2B6.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩89.5B₩4.9B₩6B5.5%9.9%101.8%
2023₩92.4B-₩100M-₩2.2B−0.2%−2.7%93.9%
2024₩97.6B-₩12.1B-₩19.3B−12.4%−26.5%146.4%
2025₩116.3B-₩13.9B-₩24B−11.9%−31.3%163.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, sales rose from KRW 89.5 billion in 2022 to KRW 92.4 billion in 2023 (up 3.3%), KRW 97.6 billion in 2024 (up 5.5%) and KRW 116.3 billion in 2025 (up 19.2%), rising for three consecutive years from 2023 to 2025, with 2025 the largest year of 2022 to 2025.

Operating profit of KRW 4.92 billion in 2022 turned into an operating loss of KRW 149 million in 2023, and then the loss widened to KRW 12.1 billion in 2024 and KRW 13.9 billion in 2025. The operating margin was 5.5% in 2022, -0.2% in 2023, -12.4% in 2024 and -11.9% in 2025.

Net income attributable to controlling shareholders of KRW 5.97 billion in 2022 became a net loss of KRW 2.25 billion in 2023, and the loss expanded to KRW 19.3 billion in 2024 and KRW 24 billion in 2025.

Total net income including non-controlling interests was a KRW 24 billion net loss in 2025, the same figure as the loss attributable to controlling shareholders.

The company attributed the 2025 weakness to spending on 3D image-processing technology and on meeting product requirements from large overseas customers, and said these costs were recognized in full in current-period profit and loss without deferral.

Operating cash flow went from KRW 5.04 billion in 2022 to KRW -7.94 billion in 2023, KRW -16 billion in 2024 and KRW -20.1 billion in 2025. The debt-to-equity ratio rose from 93.9% in 2023 to 146.4% in 2024 and 163.0% in 2025, when total liabilities were KRW 125.1 billion and total equity was KRW 76.8 billion.

Quarterly results show a clear turn: after an operating profit of KRW 1.67 billion in the third quarter of 2025, the fourth quarter swung to an operating loss of KRW 13 billion, which narrowed to KRW 596 million in the first quarter of 2026.

The second quarter of 2026 returned to operating profit of KRW 1.87 billion, and the third quarter added KRW 2.17 billion.

For the third quarter's net loss attributable to controlling shareholders of KRW 8.34 billion, the company said a non-realized translation loss on foreign-currency receivables, caused by the won's sharp appreciation against the dollar at quarter-end, was recognized for accounting purposes and is separate from operating activity. Over the last four quarters, net losses attributable to controlling shareholders totaled KRW 23.7 billion.

05

Industry analysis

Drtech operates in two markets, medical imaging diagnostics and industrial non-destructive testing (NDT) equipment, and in both, competition centers on high-resolution, low-dose imaging technology.

The dynamic detector market has long been dominated by companies in Japan, the United States and France, and Drtech entered later and is expanding deliveries to global customers. The company says its detectors use proprietary low-dose, high-definition image processing and are price-competitive.

For its EXTRON C-arm, the company says radiation exposure is one-fifth or less of rival products, a claim that comes from the company. In the domestic entry-level market, the company notes that competition is among domestic makers and that price and service quality matter most.

In industrial NDT, oil and gas is the largest application and aerospace and defense the next largest, according to press reports. Because analog film has dominated pipe weld inspection, faster penetration of digital NDT solutions is expected.

In September 2025 the company said several products, including C-arm, mammography and detector lines, obtained EU Medical Device Regulation (CE MDR) certification, a standard that sets stricter clinical evaluation, safety verification and post-market requirements than the earlier directive.

Certification opens the way into European markets, but country-specific approvals and customer delivery schedules still determine when revenue is recognized. The company said detector utilization in the first quarter of 2026 was 79%, up from 66% a year earlier.

06

Outlook

For 2026 the company set a goal of continued sales growth alongside better profitability. On production, it said higher utilization of capacity built through capital spending and process upgrades could lift margins.

Regionally, it plans to widen detector supply in North America and to push C-arm and mammography systems in Asia and Latin America. It said bendable detectors have been supplied on an ODM basis to a global non-destructive testing company since the third quarter of 2026.

Beyond the 16-inch large-bore pipe product supplied to A, it reported that a 2-inch small-bore product has been approved and is nearing delivery. The Aramco and ADNOC approvals are a precondition for sales to Middle Eastern oil companies, and the size of actual orders will become visible in later supply disclosures.

The company reported first-half 2026 sales of KRW 68.9 billion, up 17% year on year and a record for a first half. It said major R&D and facility investment programs through 2025 are largely complete, and that operating cash flow has been improving since the second half of 2026.

It said it plans to meet convertible bond redemptions with cash on hand. The company's recruitment page sets a target of USD 100 million in exports for 2026. The next confirmation point is the annual operating profit and operating cash flow that will be fixed in the 2026 annual report.

07

Valuation

PER
—
PBR
0.9×
ROE
-31.0%
EPS
-₩1,421
BPS
₩4,574
Dividend per share
₩0

Because the last four quarters produced net losses, the price-to-earnings ratio is not calculated. With earnings-based multiples unavailable, the price-to-book ratio becomes the main point of comparison.

The year-end price-to-book ratio ranged from about 1.4 times to 3.9 times between 2020 and 2024, and it now sits below 1 times, under the lower end of that past range.

A low ratio of share price to net asset value shows how the market prices the company's assets, but it does not by itself show whether those assets will translate into profit. Dividends have not been paid in the periods reviewed, so dividend-based comparison is limited.

The 163.0% debt-to-equity ratio and negative operating cash flow at the end of 2025 are financial conditions to weigh alongside any asset-based multiple.

The comparison therefore rests on two facts: the low price-to-book level, and whether the quarterly return to operating profit carries through to full-year net profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Wider overseas supply and product lineup

The company said cumulative sales through the third quarter of 2026 passed KRW 100 billion, and first-half 2026 sales of KRW 68.9 billion were a record for a first half.

Volumes of the EXPEED dynamic detector rose with deliveries to global companies, and exports grew from KRW 74.3 billion in 2024 to KRW 95.4 billion in 2025. Supply to A and the Aramco and ADNOC approvals are widening the industrial segment.

Quarterly profitability improving

Operating profit turned positive at KRW 1.87 billion in the second quarter of 2026 and rose to KRW 2.17 billion in the third quarter. The first-quarter 2026 operating loss of KRW 596 million was narrower than the KRW 3.5 billion loss a year earlier.

Detector utilization rose to 79% in the first quarter of 2026 from 66% a year earlier, which the company cites as a margin driver.

Certifications and large partnerships

In September 2025 the company said multiple products, including C-arm, mammography and detector lines, received EU Medical Device Regulation certification.

A supply agreement for more than 600 C-arm units with a global healthcare company and ODM supply to a global non-destructive testing company, which reported annual revenue of roughly KRW 30 trillion, are in progress. Regulatory approvals are the foundation for wider overseas sales.

09

Bear factors

Net losses persist

Net loss attributable to controlling shareholders widened to KRW 24 billion in 2025 from KRW 19.3 billion in 2024. Over the last four quarters that loss totaled KRW 23.7 billion, and the third quarter of 2026 returned to a net loss of KRW 8.34 billion.

The company attributed part of that loss to translation of foreign-currency receivables, but the exposure that lets exchange rates move net income remains.

Balance sheet strain and cash flow

The debt-to-equity ratio was 163.0% at the end of 2025, with total liabilities of KRW 125.1 billion exceeding total equity of KRW 76.8 billion. Operating cash flow was positive at KRW 5.04 billion in 2022 but has been negative every year since 2023, reaching KRW -20.1 billion in 2025.

The company says cash flow has been improving since the second half of 2026, a claim the cash flow statement in the 2026 annual report will test.

Customer concentration and competition

The dynamic detector market has long been dominated by companies in Japan, the United States and France, and Drtech is a later entrant. Recent growth appears to rest on higher volumes from a small number of global customers, which suggests customer concentration may be high.

The export share was 82% as of the third quarter of 2025, leaving the company exposed to overseas demand and exchange rates.

10

Risk factors

Exchange rates and foreign-currency gains and losses

With a high export share, the company holds substantial foreign-currency receivables, and sharp currency moves produce unrealized translation gains or losses that feed into net income. The company said part of the third-quarter 2026 net loss of KRW 8.34 billion reflected this effect.

Net income can turn negative even when operating profit is positive, so quarterly net results need to be read separately from operating performance.

Funding and convertible bonds

In September 2025 the company decided on a third-party rights offering of about KRW 5 billion to fund facilities and operations. In August 2026 it said preparations for convertible bond repayment were on track, and in November 2026 it said it was resolving the matter with cash on hand. Whether cash flow actually improves will determine how heavy the funding burden becomes.

Approvals and delivery timing

For medical devices and NDT equipment, the timing of revenue recognition depends on country-level approvals and customer delivery schedules. EU certification and the Aramco and ADNOC approvals widen the range of possible sales, but whether actual orders and deliveries follow still has to be confirmed. Delivery of the 2-inch small-bore bendable detector is also still in progress.

11

What to watch next

  1. January–February 2027 (typical timing)

    Preliminary full-year 2026 results. The checkpoints are the change from the 2025 operating loss of KRW 13.9 billion and whether fourth-quarter results close in profit.

  2. End of March 2027 (statutory filing deadline)

    Filing of the 2026 annual report. It fixes full-year net income attributable to controlling shareholders, operating cash flow and the debt-to-equity ratio, and shows how the KRW 23.7 billion in net losses over the last four quarters fits into the full year.

  3. Mid-May 2027 (statutory filing deadline)

    The first-quarter 2027 quarterly report. It shows whether the 2026 quarterly profit run continues and whether higher utilization is reflected in margins after the KRW 596 million operating loss in the first quarter of 2026.

  4. After December 2026 (timing not set)

    Whether orders follow the Aramco and ADNOC approvals, the start of 2-inch small-bore bendable detector deliveries to A, and progress on convertible bond repayment. The company has not given specific dates for these items.

12

Overall view

Drtech's 2025 sales of KRW 116.3 billion were its first year above KRW 100 billion, and cumulative sales through the third quarter of 2026 also topped KRW 100 billion.

Operating results were in the red for three consecutive years from 2023 to 2025 before returning to operating profit in the second and third quarters of 2026.

Rising supply to overseas customers is cited as the growth driver, and higher utilization and wider certifications are presented as evidence of improving operating indicators.

On the other side, net losses attributable to controlling shareholders over the last four quarters total KRW 23.7 billion, and the third-quarter net loss reflected a translation loss tied to exchange rates.

A 163.0% debt-to-equity ratio and KRW -20.1 billion in operating cash flow in 2025 remain balance sheet challenges. A low price-to-book level shows how the share price compares with net assets, but whether quarterly profits carry through to full-year net income is the central question.

The next checkpoints are the preliminary 2026 full-year results and the cash flow statement in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. fnnews.com
  2. supple.kr
  3. sportalkorea.com
  4. fnnews.com
  5. thevc.kr
  6. mt.co.kr
  7. pharm.edaily.co.kr
  8. jobkorea.co.kr
  9. pharm.edaily.co.kr
  10. m.thinkpool.com
  11. vegannews.co.kr
  12. mt.co.kr
  13. comp.fnguide.com
  14. mt.co.kr
  15. supple.kr
  16. job-post.co.kr
  17. m.news.nate.com
  18. investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis